Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Composition 5-amino-1MQ: 50 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Investigation of NNMT inhibition and its downstream metabolic effects Studies on NAD+ metabolism and energy homeostasis in preclinical models Development of analytical methods (HPLC/LC-MS) for small-molecule quantitation Stability and solubility assessment of 5-amino-1MQ under laboratory storage conditions Documentation Lot-specific COA available Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
A part of Watch Medier Senior P&C Business Partner Global Clinical Lead, Clinical Development, Migraine & Pain Rdgiver og forhandler med flair for pipeline og partnerskaber (Pipeline Insights & Engagement Advisor) - vil du vre med til at sikre fremtidens adgang til nye lgemidler
A provider can help develop a plan for tapering or transitioning off the medication if needed
These patterns may reflect shifts in prescribing behavior following updated coverage
Key Takeaways Starting dose: 2mg once weekly for the first 4 weeks to assess tolerance Titration schedule: Increase every 4 weeks: 2mg 4mg 8mg 12mg (max) Half-life: Approximately 6 days, reaching steady state in 4-5 weeks Injection frequency: Once weekly on the same day each week Microdosing option: Some users split doses for improved tolerability Investigational Drug: Retatrutide is NOT FDA-approved and is currently only available through clinical trials
This ensures secure transactions , reliable dispatch , and discreet delivery for every order
